1-Azatricyclo[7.3.1.05,13]trideca-3,5(13),6,11-tetraen-2-one

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 1-Azatricyclo[7.3.1.05,13]trideca-3,5(13),6,11-tetraen-2-one
• 英文别名: 1-azatricyclo[7.3.1.05,13]trideca-3,5(13),6,11-tetraen-2-one
• 化学式: C₁₂H₁₁NO
• 分子量: 185.22
• InChiKey: QIRDEANKBHGEHE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  14
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• Methods of treating cancer patients with farnesyltransferase inhibitors
  申请人：Kura Oncology, Inc.

  公开号：US11124839B2

  公开（公告）日：2021-09-21

  The present invention relates to the field of molecular biology and cancer biology. Specifically, the present invention relates to methods of treating a subject with a farnesyltransferase inhibitor (FTI) that include determining whether the subject is likely to be responsive to the FTI treatment based on HRAS mutation status in the subject.

  本发明涉及分子生物学和癌症生物学领域。具体而言，本发明涉及使用法尼基转移酶抑制剂（FTI）治疗受试者的方法，包括根据受试者的HRAS突变状态来确定该受试者是否可能对FTI治疗有反应。
• METHODS OF TREATING CANCER PATIENTS WITH FARNESYL TRANSFERASE INHIBITORS
  申请人：Kura Oncology, Inc.

  公开号：EP3277842A1

  公开（公告）日：2018-02-07
• FARNESYLTRANSFERASE INHIBITORS FOR USE IN METHODS OF TREATING CANCER
  申请人：Kura Oncology, Inc.

  公开号：EP3534885A2

  公开（公告）日：2019-09-11
• METHODS OF TREATING CANCER PATIENTS WITH FARNESYLTRANSFERASE INHIBITORS
  申请人：Kura Oncology, Inc.

  公开号：US20180187266A1

  公开（公告）日：2018-07-05

  The present invention relates to the field of molecular biology and cancer biology. Specifically, the present invention relates to methods of treating a subject with a farnesyltransferase inhibitor (FTI) that include determining whether the subject is likely to be responsive to the FTI treatment based on HRAS mutation status in the subject.
• [EN] METHODS OF TREATING CANCER PATIENTS WITH FARNESYL TRANSFERASE INHIBITORS<br/>[FR] MÉTHODES DE TRAITEMENT DE PATIENTS CANCÉREUX À L'AIDE D'INHIBITEURS DE FARNÉSYLTRANSFÉRASES
  申请人：KURA ONCOLOGY INC

  公开号：WO2017031101A1

  公开（公告）日：2017-02-23

  The present invention relates to the field of molecular biology and cancer biology. Specifically, the present invention relates to methods of treating a subject with a farnesyltransferase inhibitor (FTI) that include determining whether the subject is likely to be responsive to the FTI treatment based on genotyping and expression profiling of certain immunological genes and RAS mutation status in the subject.